Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 74 publications
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).
Journal: American journal of hematology
Published: June 25, 2026
Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.
Journal: American journal of hematology
Published: May 12, 2026
Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia.
Journal: Blood. Red cells & iron
Published: May 04, 2026
Promoter TERT-Related Hematopoietic Somatic Mosaicism in Patients With Telomere Biology Disorders.
Journal: American journal of hematology
Published: April 22, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.
Journal: Blood cancer journal
Published: March 13, 2026
Characteristics of clonal cytopenia of undetermined significance in the presence of ZRSR2 mutations.
Characteristics of clonal cytopenia of undetermined significance in the presence of ZRSR2 mutations.
Journal: Haematologica
Published: February 26, 2026
Blast Clearance Dynamics and Time to Response Across IDH1- and IDH2-Mutated AML.
Journal: EJHaem
Published: November 17, 2025
Artificial intelligence in myeloid malignancies: Clinical applications of machine learning in myelodysplastic syndromes and acute myeloid Leukemia.
Journal: Blood reviews
Published: August 13, 2025
Last Updated: 09/26/2026